Literature DB >> 569589

Evidence that a nigral gabaergic--cholinergic balance controls posture.

G M De Montis, M C Olianas, G Serra, A Tagliamonte, J Scheel-Krüger.   

Abstract

The intranigral injection of kainic acid (k.a.) (3.5 nM/s.n.) produced a lesion which resulted in a decreased muscarinic receptor binding capacity and in a decreased choline acetyl transferase (CAT) activity confined to the pars reticulata. The unilateral, intranigral injection of carbachol in the substantia nigra (s.n.) produced turning, ipsilateral to the injected side, of dose-related intensity, which was antagonized by scopolamine given either i.p. or intranigrally together with carbachol. The bilateral, intranigral injection of carbachol produced rigid catalepsy, highly resistant to apomorphine administration and antagonized by scopolamine. On the other hand, the catalepsy produced by intranigral picrotoxin was much more sensitive to apomorphine and was disrupted by systemic scopolamine administration. Intranigral scopolamine per se produced either contralateral turning or stereotyped movements consistently, when injected unilaterally or bilaterally, respectively. In addition, scopolamine injected bilaterally in the s.n. but not in the caudate nucleus (c.n.), at the concentration of 64 nM side, was able to antagonize the haloperidol-induced catalepsy and to prevent the tremors and the muscular rigidity produced by arecoline. This effect of scopolamine was surmountable with a higher dose of arecoline. Finally, intranigral muscimol (0.44 nM/s.n.) prevented the occurrence of the parkinsonian syndrome produced by systemic arecoline. It is concluded that the muscarinic receptors present in the s.n. pars reticulata play a role in the control of posture opposite to that of the nigral GABA receptors.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 569589     DOI: 10.1016/0014-2999(79)90164-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

1.  Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.

Authors:  Zixiu Xiang; Analisa D Thompson; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  J Pharmacol Exp Ther       Date:  2011-12-01       Impact factor: 4.030

2.  Behavioural effects after cholinergic stimulation of the reticular thalamic nucleus in rats.

Authors:  W Kolasiewicz; C Sauss; F Block; K H Sontag
Journal:  J Neural Transm Gen Sect       Date:  1992

Review 3.  Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications.

Authors:  K Gale; M Casu
Journal:  Mol Cell Biochem       Date:  1981-09-25       Impact factor: 3.396

4.  Behavioral differences induced by muscimol selectively injected into pars compacta and pars reticulata of Substantia nigra.

Authors:  J Arnt; J Scheel-Krüger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-12       Impact factor: 3.000

5.  The effects of muscimol and picrotoxin injections into the cat substantia nigra.

Authors:  S Wolfarth; W Kolasiewicz; K H Sontag
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-08       Impact factor: 3.000

6.  GABAergic and glycinergic mechanisms within the substantia nigra: pharmacological specificity of dopamine-independent contralateral turning behavior and interactions with other neurotransmitters.

Authors:  J Arnt; J Scheel-Krüger
Journal:  Psychopharmacology (Berl)       Date:  1979-04-25       Impact factor: 4.530

7.  Electrophysiological actions of nicotine on substantia nigra single units.

Authors:  P B Clarke; D W Hommer; A Pert; L R Skirboll
Journal:  Br J Pharmacol       Date:  1985-08       Impact factor: 8.739

8.  Classical and non-classical neuroleptics induce supersensitivity of nigral GABA-ergic mechanisms in the rat.

Authors:  D M Coward
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

Review 9.  Physiological and behavioral studies with muscimol.

Authors:  F V DeFeudis
Journal:  Neurochem Res       Date:  1980-10       Impact factor: 3.996

10.  Decreased 3H-L-quinuclidinyl benzilate binding and muscarine receptor subsensitivity after chronic gamma-butyrolactone treatment.

Authors:  O Giorgi; M C Rubio
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.